International Clinical Trial: Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07807878) titled 'Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma' on Sept. 2.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Assistance Publique Hopitaux De Marseille

Condition: Cutaneous Melanoma

Intervention: Drug: Temozolomide (TMZ)

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: June 1, 2027

Target Sample Size: 28

To know more, visit https://clinicaltrials.gov/study/NCT07807878

Disclaimer: Curated by HT Syndicatio...